



SUNDARAM BRAKE LININGS LIMITED

Padi, Chennai - 600 050, India.

Telephone: 73580 33474
E-mail : sbl@tvssbl.com
Website : www.tvsbrakelinings.com
PAN : AADCS4888E

Secl/IV- Qr 2023-24
10th February, 2024

National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, "G" Block Bandra Kurla Complex Bandra (East), Mumbai-400 051 Scrip Code: SUNDRMBRAK	BSE Limited Floor 25, P J Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 590072
---	---

Dear Sir/Madam,

Sub: Newspaper Advertisement - Unaudited financial results

In compliance with the Regulation 47 and other applicable regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement published on 10th February, 2024 in newspapers viz. Financial Express (English) and Dinamani (Tamil) informing the unaudited financial results for the quarter and nine months ended 31st December, 2023.

This is for your kind information and records.

Thanking you,

Yours truly

for **SUNDARAM BRAKE LININGS LIMITED**

Y. SATHYAN
DGM-FINANCE & COMPANY SECRETARY

BEATS ESTIMATES**Tata Power Q3 profit rises to ₹1,076 crore**

Revenue from operations rises 4% to ₹14,651 cr

RAGHAVENDRA KAMATH
Mumbai, February 9

TATA POWER ON Friday posted a marginal growth in net profit at ₹1,076 crore in the December quarter against ₹1,052 crore in the corresponding quarter a year ago. The profit was, however, higher than analyst estimates, which had pegged it at ₹895 crore.

The company posted a growth of 4% in its revenue from operations at ₹14,651 crore in Q3FY24 compared to ₹14,129 crore in Q3FY23. Analysts had expected a revenue of ₹15,636 crore.

The company's Ebitda (earnings before interest, taxes and amortisation) was up 15% on a year-on-year basis.

**POWER PLAY**

■ Profit rises to ₹1,076 cr in Dec quarter of FY24

■ Core businesses continue to perform well during Q3 of FY24

■ During Q3, the share of core business stood at 71% against 39% a year ago

■ Co plans to take total clean energy to over 10,000 MW in next 12-24 months

The generation business posted a profit before tax (PBT) of ₹860 crore on revenues of ₹4,958 crore, while the renewables business posted a PBT of ₹463 crore on a revenue of ₹2,484 crore.

The transmission and distribution business posted a PBT of ₹612 crore on a revenue of ₹8,450 crore.

During Q3, the share of core business, including generation, transmission and distribution business, stood at 71% against 39% a year ago.

Tata Power also won its first-ever project under the tariff-based competitive bidding process during the quarter. As of December 31, 2023, the company's operational capacity was at 4,270 MW in the renewables segment, generating 6,031 mega units of green power.

Another 4,752 MW of projects under TPREL (Tata Power Renewable Energy) and 4,120 MW of projects under TPSSL (Tata Power Solar Systems) are under execution, thus taking the total clean energy capacity to over 10,000 MW in the next 12-24 months, Tata Power said.

surge in power demand, Tata Power is well-positioned to capitalise on the growth momentum with its cutting-edge, customised and cost-effective clean and green energy solutions."

PepsiCo's India growth in 'mid-single digit' in 2023

PRESS TRUST OF INDIA
New Delhi, February 9

GLOBAL BEVERAGE AND food major PepsiCo on Friday reported a "mid-single-digit" growth in the Indian market in 2023. Globally, PepsiCo saw a net revenue of \$91.47 billion in 2023, registering a growth of 5.9%, according to the latest earnings report. For the full year, developing and emerging markets such as "China and


Globally, PepsiCo saw a net revenue of \$91.47 billion in 2023, registering a growth of 5.9%

India each delivered mid-single-digit growth," PepsiCo said.

However, PepsiCo's net revenue in Africa, the Middle East, South Asia (AMESA) division, including India, was at \$6.14 billion, a decline of 4.64%. This

"primarily reflected a 21-percentage-point impact of unfavourable foreign exchange, driven primarily by the weakening of the Egyptian pound, and a net organic volume decline, partially offset by effective net pricing," it said.

"We are confident that our businesses will perform well in 2024. Category growth rates are normalising," said chairman and CEO Ramon Laguarda.

**Honasa Consumer Limited**

(formerly known as Honasa Consumer Private Limited)

CIN: U74999DL2016PLC306016

Registered office: Unit No - 404, 4th floor, City Centre,
Plot No 05, Sector-12, Dwarka, New Delhi – 110075, India

Website: www.honasa.in; Email: compliance@mamaearth.in; Telephone: 011-44123544

Extract of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023

(Amount in Rs. Million)

S No.	Particulars	Quarter ended			Nine months ended		Previous year ended
		December 31, 2023		September 30, 2023	December 31, 2022	December 31, 2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	4,882.15	4,961.08	3,821.58	14,488.10	11,048.93	14,927.48
2	Profit before exceptional items and taxes	347.19	392.05	106.53	1,078.76	197.81	136.57
3	Profit/(Loss) before tax	347.19	392.05	106.53	1,078.76	197.81	(1,410.40)
4	Profit/(Loss) after tax	259.01	294.38	71.25	800.53	107.92	(1,509.66)
5	Total comprehensive income/(loss), net of tax	260.86	297.84	74.06	802.31	111.68	(1,506.87)
6	Equity Share Capital	3,217.47	1,363.36	1,363.36	3,217.47	1,363.36	1,363.36
7	Reserves (excluding Revaluation Reserve)	-	-	-	-	-	-
8	Earnings/(Loss) per equity share (of Rs.10/- each)	0.82	0.96	0.31	2.62	0.56	(4.66)
a) Basic		0.82	0.96	0.31	2.62	0.56	(4.66)
b) Diluted		0.81	0.93	0.29	2.59	0.55	(4.66)

Note:

(a) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the Stock Exchanges, www.nseindia.com and www.bseindia.com and on the company's website www.honasa.in.

(b) Additional information on Standalone Financial Results is as follows:

S No.	Particulars	Quarter ended			Nine months ended		Previous year ended
		December 31, 2023		September 30, 2023	December 31, 2022	December 31, 2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	4,508.92	4,601.93	3,548.56	13,372.22	10,344.77	13,948.03
2	Profit/(Loss) before tax	370.69	475.69	190.85	1,214.35	405.48	(1,072.84)
3	Profit/(Loss) after tax	289.14	377.36	151.54	942.54	309.34	(1,205.56)

For and on behalf of Board of Directors of Honasa Consumer Limited

Varun Alagh
Chairperson, Whole Time Director and CEO

DIN:07597289

Gurugram

February 9, 2024

[financialexpress.epaper.in](http://www.financialexpress.com)

Biocon arm to focus on consolidation in FY25

In Europe, the firm is focusing on five high-growth nations

AYANTI BERA
Bengaluru, February 9

BIOCON BIOLOGICS, A subsidiary of pharma major Biocon, will focus on consolidating its acquisition of long-time partner Viatris' biosimilars business in the upcoming fiscal, in an effort to set a stage for its next phase of growth, CEO and MD Shreehas Tambe told FE on Friday.

The company recently completed the integration of the global biosimilars business of Viatris, which it

SHREEHAS TAMBE, CEO & MD, BIOCON BIOLOGICS



BIOCON BIOLOGICS WILL FOCUS ON CONSOLIDATING ITS ACQUISITION OF LONG-TIME PARTNER VIATRIS' BIOSIMILARS BUSINESS IN THE NEXT FISCAL

had acquired in 2022 for \$3.34 billion.

The acquisition is expected to help the company get access to commercial capabilities and supporting infrastructure in over 120 countries.

Even before the full-impact of the acquisition is seen, Bio-

con's biosimilar business managed to post a 65% rise in sales to ₹2,483 crore in the third quarter of FY24, as its biosimilars gained market share cross geographies.

In US, Semglee, its long-acting man-made-insulin, held a steady market share at about 12%, while Fulphila,

used to decrease the chance of infection, maintained around 18% market share, and Ogviri, used to treat early-stage breast cancer, had a market share of about 12%.

"In Europe, where we have seven products approved, the strategy is changing because in the past, it was only two products and two countries that the business was operational in. But now, we will operate with seven products and more than these two countries," Tambe said.

The bottomline was mainly strengthened by income from the divestiture of two non-core business assets — Biocon Biologics' Dermatology and Nephrology branded formulations business units in India — amounting to ₹350 crore and a gain of ₹456 crore from Biocon's stake dilution in Bicara Therapeutics.

In Europe, the company is focusing on five high-growth countries — France, Germany, UK, Spain and Italy.

On Thursday, its parent Biocon posted a revenue from operations of ₹3,954 crore in Q3, up 34% year-on-year. It swung back to profit in Q3 at ₹660 crore, compared to the loss of ₹42 crore in the year-ago period.

The bottomline was mainly strengthened by income from the divestiture of two non-core business assets — Biocon Biologics' Dermatology and Nephrology branded formulations business units in India — amounting to ₹350 crore and a gain of ₹456 crore from Biocon's stake dilution in Bicara Therapeutics.

TVS SUNDARAM BRAKE LININGS LIMITED

CIN:L34300TN1974PLC006703

Regd Office: Padi, Chennai - 600 050, Tel:044-26257853; Fax: 044-26254770

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2023

S. No.	Particulars	Quarter ended		Nine months ended		Previous Year Ended 31.03.2023
		31.12.2023	31.12.2022	31.12.2023	31.12.2022	
		Unaudited	(Unaudited)	Unaudited	(Unaudited)	
1	Total Income from operations	8,486.11	8,768.04	26,464.14	26,541.94	35,760.38
2	Net Profit / (Loss) for the period (before Tax, Exception					

